Abniki Reza, Tashakor Amirhossein, Masoudi Melika, Pourdad Arezoo, Mansury Davood
Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2024 Jul 29;13:39. doi: 10.4103/abr.abr_345_23. eCollection 2024.
The emergence of coronavirus disease in 2019 (COVID-19) appears to be having an impact on antibiotic resistance patterns. Specific circumstances during the COVID-19 era may have played a role in the spread of antimicrobial resistance (AMR). This study aimed to look at the changes in AMR patterns of , , and at Al-Zahra Hospital.
From March 2021 to January 2023, 3651 clinical samples were collected from patients hospitalized at Isfahan's Al-Zahra Hospital. The Clinical and Laboratory Standards Institute recommended procedures for detecting gram-negative bacteria and assessing antibiotic susceptibility were used. We divided the information into three years.
Highest resistance rates were seen in to Ciprofloxacin (98.0%) and Ampicillin-Sulbactam (97.0%). For the resistance rate for Ceftazidime (36.1), Levofloxacin (37.8), and Meropenem (47.1) dropped seriously in 2022.
During the second year of the pandemic in central Iran, all three species studied showed rising rates of AMR. This can be attributable to two peaks within Iran on May 6, 2021 and August 27, 2021. The results of this study show that , , and bacteria in central Iran have a higher level of antibiotic resistance than previously studied strains before the pandemic.
2019年冠状病毒病(COVID-19)的出现似乎正在对抗生素耐药模式产生影响。COVID-19时代的特定情况可能在抗菌药物耐药性(AMR)的传播中起到了作用。本研究旨在观察伊斯法罕扎赫拉医院、 、 和 的AMR模式变化。
2021年3月至2023年1月,从伊斯法罕扎赫拉医院住院患者中收集了3651份临床样本。采用临床和实验室标准协会推荐的检测革兰氏阴性菌和评估抗生素敏感性的程序。我们将信息分为三年。
对环丙沙星(98.0%)和氨苄西林-舒巴坦(97.0%)的耐药率最高。对于 ,头孢他啶(36.1)、左氧氟沙星(37.8)和美罗培南(47.1)的耐药率在2022年大幅下降。
在伊朗中部大流行的第二年,所研究的所有三个物种的AMR率都在上升。这可能归因于2021年5月6日和2021年8月27日伊朗境内的两个高峰。本研究结果表明,伊朗中部的 、 和 细菌比大流行前先前研究的菌株具有更高水平的抗生素耐药性。